Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2022 - Wrap Up
ASH 2021 - Myelofibrosis
ASH 2021 Systemic Mastocytosis Wrap-Up
AVBCC 2020
ASCO 2020 - Cholangiocarcinoma
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Web Exclusives
Conquer Cancer Foundation of ASCO & Swim Across America Team Up To Create Young Investigator Award
ASCO 2019
,
In the News
,
ASCO
Web Exclusives
— February 19, 2019
Swim Across America is supporting the American Society of Clinical Oncology (ASCO) and ASCO’s Conquer Cancer Foundation with the creation of the Conquer Cancer Foundation of ASCO—Swim Across America Young Investigator Award (YIA).
Read Article
February 8, 2019 - FDA Approvals, News & Updates
FDA Approvals, News & Updates
,
In the News
Web Exclusives
— February 8, 2019
Read Article
Maintenance Therapy with Ixazomib Significantly Prolongs Progression-Free Survival Following Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Results from the TOURMALINE-MM3 Trial
Maintenance Therapy
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
— February 1, 2019
San Diego, CA—In patients with multiple myeloma (MM), the use of drug therapy as maintenance has been shown to prolong the length of time the disease is controlled. Specifically, use of maintenance therapy may affect overall survival, particularly when it is used after an autologous stem-cell transplant (ASCT).
Read Article
February 1, 2019 - FDA Approvals, News & Updates
FDA Approvals, News & Updates
,
In the News
Web Exclusives
— February 1, 2019
Read Article
Government Shutdown Impacts FDA Drug Approvals
FDA Approvals, News & Updates
,
In the News
Web Exclusives
— January 14, 2019
Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold. The FDA recently posted on its website a notice alerting the public of its current operational status.
Read Article
Once-Weekly Carfilzomib for Patients with Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival
By
Walter Alexander
2018 EHA Congress Highlights
,
Multiple Myeloma
,
Hematologic Malignancies
Web Exclusives
— August 28, 2018
Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.
Read Article
New Clues to Mismatch Repair and PD-1/PD-L1 Status and Survival in Patients with Gastric or Esophageal Cancer
By
Charles Bankhead
Gastrointestinal Cancers
Web Exclusives
— August 20, 2018
San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.
Read Article
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
ASH 2017
,
Multiple Myeloma
,
Palliative Care
,
Hematologic Malignancies
,
ASH
Web Exclusives
— August 20, 2018
Read Article
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
By
Wayne Kuznar
NCCN Annual Conference
,
Value in Oncology
Web Exclusives
— July 31, 2018
Experts at this roundtable discussion addressed high patient costs, achieving greater value in oncology care, and the desire for access to comparative data.
Read Article
Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer
FDA Approvals, News & Updates
Web Exclusives
— July 24, 2018
On February 14, 2018, apalutamide (Erleada; Janssen Pharmaceuticals), an androgen receptor inhibitor, received accelerated approval by the FDA for the treatment of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). Apalutamide is the first treatment approved by the FDA for patients with nonmetastatic CRPC, and was approved under the FDA priority review process.
Read Article
Page 8 of 10
1
2
3
4
5
6
7
8
9
10
View the Lastest Issue of VBCC
Read Issue
Top Trending Articles
1.
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management
2.
Neoadjuvant Chemoimmunotherapy May Be New Standard of Care for Patients with Resectable NSCLC
Phoebe Starr
3.
How oncologists can control costs at the point of care
Ajeet Gajra, MD, FACP
,
Stephanie Mayfield, PharmD
,
Kathy Oubre, MS
,
Tanya Park
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ASCO 2022 - Wrap Up
ASH 2021 - Myelofibrosis
ASH 2021 Systemic Mastocytosis Wrap-Up
AVBCC 2020
ASCO 2020 - Cholangiocarcinoma
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
VBCC
Print Edition
VBCC
Weekly e‑Newsletter
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
VBCC
's
Privacy Policy
, and
VBCC
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION